Trans-developmental stability of self-criticism as a core target in adolescent anxiety-depression comorbidity: Insights from stage-specific network analysis and in silico interventions
Journal of Affective Disorders · 2026-07 · 405 · 121537
DOI: 10.1016/j.jad.2026.121537 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Affective Disorders, 2026-07. Verfasst von Yichen Li und 2 weiteren Autor:innen. Beteiligte Einrichtung: Beijing Key Laboratory of Learning and Cognition, School of Psychology, Capital Normal University, Beijing, PR China. Hauptthemen laut MEDLINE: Anxiety Disorders, Self Concept, Self-Assessment, Depressive Disorder. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 67 Literaturangaben. Gefördert von: Beijing Municipal Social Science Foundation.
Themen: Depression
Abstract (Originalsprache)
Adolescent anxiety-depression comorbidity constitutes a pressing public health challenge. While personality vulnerability (PV)-comprising dependency and self-criticism-is a key transdiagnostic mechanism, its developmental stability versus stage-specificity of these dimensions as an intervention target remains unresolved. This study leveraged stage-specific network analysis and in silico interventions across early (11-13), middle (14-16), and late (17-19) adolescence (N = 73,669) to identify optimal vulnerable targets for anxiety-depression networks. Bayesian hypothesis testing evaluated evidential support for network edges. Results identified SC3 (disappointing others) as a trans-developmentally stable core node and the primary bridge connecting PV to symptoms, with Bayesian analyses strongly supporting the strongest pathway between SC3 and PHQ6 (guilt). Crucially, in silico interventions quantified downstream effects on comorbid symptoms via iterative aggravation and alleviation of each vulnerable node's value. Results revealed distinct functional dynamics. In aggravating simulations, SC3 consistently emerged as the most potent trans-developmental trigger. Conversely, alleviating simulations revealed a developmental gradient: while dependency nodes demonstrated comparable symptom reduction to SC2 (far from how I would like to be) in early adolescence, SC2 solidified as the statistically dominant maintainer in middle and late adolescence. These findings offer hypothesis-generating insights for a developmentally tailored strategy: prioritizing the desensitization of interpersonal shame (SC3) for trans-developmental prevention, while shifting treatment focus from early relational antecedents to restructuring the overarching, internalized ideal-self discrepancy (SC2) in older adolescents.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Beijing Key Laboratory of Learning and Cognition, School of Psychology, Capital Normal University, Beijing, PR China.
- Beijing Key Laboratory of Learning and Cognition, School of Psychology, Capital Normal University, Beijing, PR China. Electronic address: dengyanhe@cnu.edu.cn.
Förderung
- Beijing Municipal Social Science Foundation
Zitieren
APA
Li, Y., Li, P., & Deng, Y. (2026). Trans-developmental stability of self-criticism as a core target in adolescent anxiety-depression comorbidity: Insights from stage-specific network analysis and in silico interventions. Journal of Affective Disorders, 405, 121537. https://doi.org/10.1016/j.jad.2026.121537
Vancouver
Li Y, Li P, Deng Y. Trans-developmental stability of self-criticism as a core target in adolescent anxiety-depression comorbidity: Insights from stage-specific network analysis and in silico interventions. Journal of Affective Disorders. 2026;405:121537. doi:10.1016/j.jad.2026.121537
BibTeX
@article{Li2026,
author = {Li, Yichen and Li, Peng and Deng, Yanhe},
title = {Trans-developmental stability of self-criticism as a core target in adolescent anxiety-depression comorbidity: Insights from stage-specific network analysis and in silico interventions},
journal = {Journal of Affective Disorders},
year = {2026},
volume = {405},
pages = {121537},
doi = {10.1016/j.jad.2026.121537}
}
EUVIMED